Detail akcie Molecular Sp ADS online

Business Summary: Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Molecular Partners AG (ADR) revenues was not reported. Net loss decreased 28% to SF26.7M. Lower net loss reflects Research and development expenses decrease of 16% to SF19.1M (expense), Restructuring expenses decrease from SF2.6M (expense) to SF0K, Selling/General/Admin Expense decrease of 3% to SF8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -SF1 to -SF0.70402.